Appetite & feeling full
Cagrilintide is designed around a hormone system involved in helping the body recognise when it has had enough to eat.
Explore the research →AMYLIN & WEIGHT-MANAGEMENT RESEARCH
Cagrilintide
An emerging weight-management compound designed to increase fullness and reduce appetite, cagrilintide has a growing evidence base from human trials.
AppetiteSatietyWeight management
Growing human trial evidenceClinical trials support a meaningful weight-management signal, while larger and longer studies continue to define efficacy, tolerability and the role of combination regimens.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Cagrilintide?
Cagrilintide is attracting attention because it approaches appetite and weight management from a different direction. By mimicking amylin — a hormone involved in fullness — it may help people feel satisfied for longer, which is why there is particular interest in combining it with GLP-1-based treatments.
Weight management
Weight loss is the main focus of cagrilintide's clinical development and the area generating the most interest.
Explore the research →Metabolic health
Researchers are also watching whether weight loss with cagrilintide brings improvements in other measures of metabolic health.
Explore the research →Combination potential
A major part of the buzz around cagrilintide comes from combining it with other weight-management treatments, particularly semaglutide.
Explore the research →THE SCIENCE BIT
A fullness signal inspired by amylin.
Amylin is a hormone released alongside insulin after eating. Cagrilintide is a long-acting analogue that activates amylin and calcitonin receptor systems.
An amylin receptor combines a calcitonin receptor with an accessory protein called a RAMP. These signals help explain the interest around fullness and reduced food intake, including studies with semaglutide.
See the studies & trials →- Amylin receptors
- Fullness-related signalling
- Calcitonin receptor
- Part of the receptor family
- RAMP proteins
- Help form amylin receptors
How this connects to the research
Human weight-management trials and receptor-structure studies support different parts of the story.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Cagrilintide connects with the body
These are the tissues and biological systems behind the interest in Cagrilintide.
- Brainstem
- Meal-related appetite signals.
- Brain networks
- Food-intake regulation.
- Gut
- The wider satiety conversation.
The research behind the interest
Appetite & feeling full
Cagrilintide is designed around a hormone system involved in helping the body recognise when it has had enough to eat.
Human studies support effects on appetite and body weight that fit with this role in meal-related fullness.
Human trial evidenceExplore the studies →Weight management
Weight loss is the main focus of cagrilintide's clinical development and the area generating the most interest.
Dose-ranging human trials have reported meaningful average weight loss compared with placebo.
Growing human evidenceExplore the studies →Metabolic health
Researchers are also watching whether weight loss with cagrilintide brings improvements in other measures of metabolic health.
Trials monitor blood sugar, cholesterol, waist measurements and related markers, although weight remains the clearest outcome so far.
Developing supporting evidenceExplore the studies →Combination potential
A major part of the buzz around cagrilintide comes from combining it with other weight-management treatments, particularly semaglutide.
Combination studies are testing whether targeting appetite in complementary ways can produce greater weight loss while remaining tolerable.
Active clinical investigationExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableOnce-weekly cagrilintide for weight management in people with overweight and obesity ↗
706 participants randomized across cagrilintide 0.3–4.5 mg, liraglutide and placebo groups
SubcutaneousOnce weekly26 weeks
Mean weight reductions ranged from 6.0% to 10.8% across cagrilintide doses versus 3.0% with placebo under the trial-product estimand.
Gastrointestinal events and administration-site reactions were the most frequent adverse events.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
✓
Clinical efficacyStrong
4/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceDeveloping
3/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Cagrilintide research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Appetite
RESEARCH AREA 02Satiety
RESEARCH AREA 03Weight management
RESEARCH AREA 04Combination research
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Cagrilintide
Cagrilintide draws interest from people looking for stronger fullness, less hunger and another route to weight management. The direct human signal is encouraging, especially in combination research, but it remains an investigational treatment.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Fullness that lasts beyond the meal
People are interested in feeling satisfied with less food and being less drawn back to snacks. Its amylin-based mechanism attracts those exploring appetite control beyond the GLP-1 pathway.
- What makes a report informative
- Comfortable meal satisfaction and hunger between meals.
- What can muddy the picture
- Nausea and comfortable fullness need to be described separately.
Weight-loss progress after a plateau
Some interest comes from frustration with stalled weight loss. The hope is renewed progress, but a plateau can reflect changing energy needs, adherence or fluid variation as well as appetite.
- What makes a report informative
- Longer-term weight and waist trends with the full treatment history.
- What can muddy the picture
- Switching or adding compounds prevents a clean comparison with the prior treatment.
The semaglutide combination
Combination interest reflects the idea that amylin and GLP-1 signals may complement each other. The evidence relates to studied combinations, while informal stacking accounts introduce different products and contexts.
- What makes a report informative
- The exact formulation and whether it matches the clinical research.
- What can muddy the picture
- Investigational product reports cannot establish that an informal combination has the trial result.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Stronger fullness after meals
Human findings & limits
Dose-finding trials support meaningful weight reduction consistent with amylin-based appetite effects.
Laboratory & animal context
Amylin signalling affects satiation, gastric function and meal-related appetite control.
What this means: A credible human effect under investigation, with individual response and tolerability still variable.
Weight loss without relying only on GLP-1
Human findings & limits
Cagrilintide alone produced a dose-related weight-loss signal in phase 2.
Laboratory & animal context
Its amylin pathway is distinct from GLP-1 receptor signalling.
What this means: Supported by trial evidence, though the treatment is not yet an established standalone standard.
Added effect with Semaglutide
Human findings & limits
REDEFINE trials tested the combination directly and reported substantial weight loss, while tolerability remains part of the benefit–risk picture.
Laboratory & animal context
Complementary appetite pathways provide the biological rationale for combination treatment.
What this means: Direct combination evidence exists; it applies to the studied formulation and protocol, not informal mixing.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Cagrilintide remains investigational; published doses describe clinical-trial protocols rather than an approved treatment regimen.
PUBLISHED HUMAN RESEARCH
View source ↗Phase 2 dose-finding trial ↗
Adults with overweight or obesity without type 2 diabetes
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with overweight or obesity without type 2 diabetes. Route: Injection under the skin (SubQ). The study lasted 26 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | Dose-dependent escalation |
|---|---|
| Later or target amount | 0.3 mg to 4.5 mg weekly study groups |
| How often? | once a week |
| How was it given? | Injection under the skin (SubQ) |
| How long? | 26 weeks |
See the exact study wording +
Start / initial: Dose-dependent escalation
End / target: 0.3 mg to 4.5 mg weekly study groups
Frequency: Once weekly
Route: Subcutaneous
Study duration: 26 weeks
Investigational trial dosing; not a recommendation.
COMMUNITY DISCUSSION
Investigational · trial-led discussionWhat people commonly discuss
STARTING APPROACHES
Community discussion often borrows the lowest 0.3 mg weekly phase-2 study arm. That was a randomized research dose, not a validated consumer starting amount.
DURATION / CYCLES
The phase-2 dose-finding study ran for 26 weeks with structured escalation. Informal schedules cannot be assumed to reproduce that protocol.
MAINTENANCE DISCUSSION
No authorised maintenance dose exists. The studied 0.3–4.5 mg weekly arms and CagriSema programmes belong to specific trial designs.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Weekly trial context
Human trial · escalation needs protocol detailThe phase 2 study tested weekly target-dose arms over 26 weeks with initial escalation. Target-dose arms are not a starting ladder. Record the actual assigned or prescribed schedule; no escalation amounts are inferred here.
Form and route: Subcutaneous trial formulation
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
The main known burden is gastrointestinal; longer-term use is still being defined
What the current evidence saysNausea, vomiting, diarrhoea, constipation and injection-site reactions feature in the human programme. Because cagrilintide remains investigational, current trial monitoring should not be replaced by informal dose copying.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Severe or persistent gastrointestinal symptoms, dehydration or an inability to maintain food and fluid intake needs clinical assessment. Combination products must be assessed as combinations.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
4 sourcesSources used on this profile
Bibliographic recordOnce-weekly cagrilintide for weight management in people with overweight and obesityPubMed ↗Original publicationOnce-weekly cagrilintide for weight management in people with overweight and obesityJournal / DOI ↗Trial registryOnce-weekly cagrilintide for weight management in people with overweight and obesityClinicalTrials.gov ↗Peer-reviewed combination trialSafety and uncertaintyREDEFINE 1 ↗
CURRENT STATUS
How to interpret its position today
Investigational treatment
Cagrilintide has a growing human trial programme but no authorised standalone dosing schedule in this profile.
Phase-2 trial · PubMed ↗Direct CagriSema evidence
Cagrilintide and semaglutide have been studied together in phase-3 programmes. Results belong to the tested co-formulation and protocol.
REDEFINE 1 · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.